1. In this randomized, placebo controlled study of
HER2-positive
breast cancer patients receiving
trastuzumab, use of preventative lisinopril or carvedilol did not significantly reduce cardiotoxicity compared to placebo. 2. For patients undergoing therapy with trastuzumab combined with anthracyclines, use of either carvedilol or lisinopril was associated with a reduced risk of cardiotoxicity compared to placebo. […]